Processa Pharma Files 8-K on Other Events, Financials

TL;DR

**Processa Pharma filed a routine 8-K, confirming its Nasdaq listing and compliance.**

AI Summary

Processa Pharmaceuticals, Inc. filed an 8-K on January 25, 2024, to report "Other Events" and "Financial Statements and Exhibits." This filing primarily serves to update the public record regarding the company's current status and its common stock, which trades under the symbol PCSA on the Nasdaq Capital Market. For investors, this filing is a routine update, confirming the company's continued compliance with SEC reporting requirements and its listing on a major exchange, which is important for liquidity and visibility.

Why It Matters

This filing is a standard procedural update, confirming Processa Pharmaceuticals' ongoing compliance with SEC regulations and its listing on the Nasdaq Capital Market, which is crucial for investor confidence and stock liquidity.

Risk Assessment

Risk Level: low — This 8-K is a standard, informational filing with no new material financial or operational disclosures that would significantly alter the company's risk profile.

Analyst Insight

A smart investor would view this as a routine compliance filing, indicating no immediate need for action. It confirms the company's continued listing and regulatory adherence, which is a baseline expectation for publicly traded companies.

Key Numbers

• 001-39531 — Commission file number (identifies Processa Pharmaceuticals' registration with the SEC)
• 2024-01-25 — Date of Report (the earliest event reported in the filing)
• $.0001 — Par value of common stock (the nominal value assigned to each share of common stock)
• 443-776-3133 — Registrant's Telephone Number (contact number for Processa Pharmaceuticals, Inc.)

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• Nasdaq Capital Market (company) — the exchange where Processa's common stock is registered
• PCSA (company) — the trading symbol for Processa Pharmaceuticals' common stock
• Delaware (company) — state of incorporation for Processa Pharmaceuticals, Inc.
• 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076 (dollar_amount) — business address of Processa Pharmaceuticals, Inc.

FAQ

Filing Documents

• form8-k.htm (8-K) — 36KB
• ex99-1.htm (EX-99.1) — 22KB
• 0001493152-24-003705.txt ( ) — 233KB
• pcsa-20240125.xsd (EX-101.SCH) — 3KB
• pcsa-20240125_lab.xml (EX-101.LAB) — 33KB
• pcsa-20240125_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 7380 Coca Cola Drive , Suite 106 , Hanover , Maryland 21076 (Address of Principal Executive Offices, Including Zip Code) ( 443 ) 776-3133 (Registrant's Telephone Number, Including Area Code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock: Par value $.0001 PCSA Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. On January 25, 2024, Processa Pharmaceuticals, Inc. (the "Company") issued a press release announcing the successful completion of Phase 1b safety evaluation of NGC-Cap in patients with advanced cancer resulting in recommended Phase 2 doses. Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Press release announcing the successful completion of Phase 1B safety evaluation of NGC-Cap in patients with advanced cancer resulting in recommended Phase 2 doses. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on January 25, 2024. PROCESSA PHARMACEUTICALS, INC. Registrant By: /s/ George Ng George Ng Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR